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Marijuana has been used for thousands of years as a
treatment for medical conditions. However, unto-
ward side effects limit its medical value. Here, we
show that synaptic and cognitive impairments
following repeated exposure to D9-tetrahydrocan-
nabinol (D9-THC) are associated with the induction
of cyclooxygenase-2 (COX-2), an inducible enzyme
that converts arachidonic acid to prostanoids in
the brain. COX-2 induction by D9-THC is mediated
via CB1 receptor-coupled G protein bg subunits.
Pharmacological or genetic inhibition of COX-2
blocks downregulation and internalization of gluta-
mate receptor subunits and alterations of the
dendritic spine density of hippocampal neurons
induced by repeated D9-THC exposures. Ablation
of COX-2 also eliminates D9-THC-impaired hippo-
campal long-term synaptic plasticity, spatial, and
fear memories. Importantly, the beneficial effects of
decreasing b-amyloid plaques and neurodegenera-
tion by D9-THC in Alzheimer’s disease animals are
retained in the presence of COX-2 inhibition. These
results suggest that the applicability of medical mari-
juana would be broadened by concurrent inhibition
of COX-2.INTRODUCTION
Marijuana has been used for thousands of years to treat chronic
pain, multiple sclerosis, cancer, seizure disorders, nausea,
anorexia, and inflammatory and neurodegenerative diseases
(Robson, 2001; Russo, 2007). However, the undesirable neuro-
psychological and cognitive side effects greatly limit the medical
use of marijuana (Carlini, 2004). The major intoxicating effects of
cannabis are the impairments in synaptic and cognitive function1154 Cell 155, 1154–1165, November 21, 2013 ª2013 Elsevier Inc.(Pope et al., 2001; Solowij et al., 2002; Messinis et al., 2006).
These untoward effects are also the primary consequences of
cannabis abuse. However, there are no currently FDA-approved
effective medications for prevention and treatment of these
cannabis-related disorders.
As it is clear now, D9-tetrahydrocannabinol (D9-THC) is the
major psychoactive ingredient of marijuana (Gaoni and Mechou-
lam, 1964), and its effects are largely mediated through cannabi-
noid receptors (CB1R or CB2R), which are pertussis toxin
(PTX)-sensitive G-protein-coupled receptors (Howlett, 1998;
Pertwee et al., 2010). Previous studies demonstrate that
deficits in long-term synaptic plasticity, learning, and memory
by D9-THC exposure are primarily mediated through CB1R
expressed in the brain (Lichtman and Martin, 1996; Hoffman
et al., 2007; Puighermanal et al., 2009; Fan et al., 2010; Han
et al., 2012). However, the molecular mechanisms underlying
the synaptic and cognitive deficits elicited by repeated D9-THC
exposure are largely unknown.
In the present study, we unexpectedly observed that D9-THC
increases expression and activity of cyclooxygenase-2 (COX-2),
an inducible enzyme that converts arachidonic acid to prosta-
noids both in vitro and in vivo via a CB1R-dependent mecha-
nism. This action is opposite to the observations where the
endogenous cannabinoid 2-arachidonylglycerol (2-AG) induces
a CB1R-dependent suppression of COX-2 activity and expres-
sion in response to proinflammatory and excitotoxic insults
(Zhang and Chen, 2008). The differential modulation of COX-2
by the exogenous cannabinoid D9-THC and endogenous canna-
binoid 2-AG appears to result from intrinsic properties of the
CB1R-coupled G protein. The COX-2 induction by D9-THC is
mediated via Gbg subunits, whereas COX-2 suppression by
2-AG is mediated through the Gai subunit. Interestingly, the
impairments in hippocampal long-term synaptic plasticity,
spatial, and fear memories induced by repeated D9-THC expo-
sure can be occluded or attenuated by pharmacological or ge-
netic inhibition of COX-2. Finally, the beneficial effects of
reducing Ab and neurodegeneration by D9-THC are retained in
the presence of COX-2 inhibition. Our results reveal a signaling
pathway that is linked to synaptic and cognitive deficits induced
Figure 1. D9-THC In Vivo Exposure In-
duces CB1R-Dependent Activation and
Elevation of COX-2 Expression in the Hippo-
campus
(A and B) D9-THC induces a dose- and time-
dependent increase in hippocampal COX-2 ex-
pression (n = 5).
(C) D9-THC increases synthesis of PGE2, and
the increase is blocked by Celebrex (Celeb)
or genetic inhibition of COX-2 (COX-2 knock-
out). PGE2 was detected 4 hr after D
9-THC
injection (10 mg/kg). Celebrex (10 mg/kg) was
injected 30 min prior to D9-THC injection (n = 10/
group).
(D) COX-2 is persistently elevated in animals that
received repeated injections ofD9-THC (10mg/kg,
i.p.) once a day for 7 consecutive days. COX-2
was analyzed 24 hr after secession of the last
injection (n = 3).
(E) COX-2 induction by D9-THC (10 mg/kg) is
blocked by Rimonabant (RIM, 5 mg/kg). Hippo-
campal COX-2 was detected 4 hr after D9-THC
injection (n = 3). RIM was injected 30 min prior to
D9-THC injection.
(F) D9-THC fails to increase COX-2 in CB1R
knockout mice (n = 3).
(G)D9-THC increases COX-2 both in neurons and astroglial cells in culture, and the increase is blocked by RIM. COX-2 was assayed 12 hr after treatments (n = 6).
All the data are presented as mean ± SEM; *p < 0.05, **p < 0.01 compared with the vehicle controls, #p < 0.05, and ##p < 0.01 compared with D9-THC (one-way
ANOVA, Fisher’s PLSD). See also Figures S1 and S7.by D9-THC exposure, suggesting that D9-THC would display its
beneficial properties with fewer undesirable side effects when its
COX-2 induction effect is inhibited, which may form a therapeu-
tic intervention for medical treatments.
RESULTS
D9-THC Induces Dose- and Time-Dependent Increase in
COX-2 Expression
Identification of CBRs led to discovery of several endogenous
cannabinoids, including anandamide (AEA) and 2-arachidonyl-
glycerol (2-AG), which are the most-studied endocannabinoids
involved in a variety of physiological, pharmacological, and path-
ological processes (Kano et al., 2009; Pertwee et al., 2010).
2-AG, the most abundant endocannabinoid, plays significant
roles in synaptic modification, resolution of neuroinflammation,
and neuronal survival (Alger, 2009; Chevaleyre et al., 2006;
Lovinger, 2008; Panikashvili et al., 2001; Zhang and Chen,
2008). In particular, its anti-inflammatory and neuroprotective
effects in response to proinflammatory and neurotoxic insults
appear to be through limiting COX-2 signaling (Chen et al.,
2011; Du et al., 2011; Zhang and Chen, 2008). Because acute
inhibition of COX-2 by selective COX-2 inhibitors has been
shown to decrease hippocampal long-term potentiation (LTP)
and impairs memory consolidation (Chen et al., 2002; Teather
et al., 2002; Cowley et al., 2008), we thus wondered whether
impairments of synaptic plasticity and memory by marijuana
result from a COX-2 suppressive effect. To assess this, we first
analyzed hippocampal expression and activity of COX-2 in
mice that received D9-THC. Unexpectedly, in vivo exposure to
D9-THC produced a dose- and time-dependent induction of
COX-2 in the brain, rather than suppression (Figures 1A andC1B), whereas expression of COX-1 was unaffected by D9-THC
(Figure S1A available online). The increase in COX-2 expression
induced byD9-THCwas accompanied by elevated production of
prostaglandin E2 (PGE2), which could be inhibited by the selec-
tive COX-2 inhibitor Celebrex or genetic inhibition of COX-2
(Figures 1C and S1B). To confirm the ability of exogenous canna-
binoids to induce COX-2, we assessed COX-2 expression and
PGE2 production in animals injected with the synthetic cannabi-
noid CP55,940 (CP). As expected, CP produced more pro-
nounced effects on COX-2 expression and PGE2 synthesis
(Figures S1C–S1E). The increase in PGE2 could be blocked
by NS398, another selective COX-2 inhibitor. In addition, we
observed that COX-2 expression was steadily elevated in ani-
mals injected with D9-THC once daily for 7 consecutive days,
although the magnitude of increase in COX-2 was not as intensi-
fied as that of a single injection (Figure 1D). This indicates that
expression of COX-2 is persistently elevated upon repeated
exposure to D9-THC (Figure S7).
COX-2 Induction by D9-THC Is CB1R Dependent
Because undesirable side effects elicited by cannabinoids are
primarily mediated by CB1R (Lichtman and Martin, 1996; Hoff-
man et al., 2007; Han et al., 2012), we wondered whether
COX-2 induction by D9-THC is mediated via CB1R. As shown
in Figures 1E and1F, D9-THC-induced increase in COX-2 in the
hippocampus was blocked either by Rimonabant (RIM), a selec-
tive CB1R antagonist, or by genetic deletion of CB1R. To deter-
mine whether the increase in COX-2 by D9-THC occurs in
neurons or astroglial cells, we made different conditions in cul-
tures as described previously (Zhang and Chen, 2008). We found
that, although D9-THC induced a CB1R-dependent increase in
COX-2 expression both in neuronal and astroglial cell-enrichedell 155, 1154–1165, November 21, 2013 ª2013 Elsevier Inc. 1155
cultures, the increase was more pronounced in astroglial cell-
enriched cultures than in neuronal culture (Figure 1G). Our data
provide convincing evidence that COX-2 induction by D9-THC
both in vivo and in vitro is mediated via CB1R.
COX-2 Induction by D9-THC Is via CB1R-Coupled
G Protein bg Subunits
Because the suppression of COX-2 by 2-AG in response to
proinflammatory stimuli occurs via a CB1R-dependent mecha-
nism (Zhang and Chen, 2008), we questioned why the exoge-
nous cannabinoid D9-THC increases COX-2 and why the
endogenous cannabinoid 2-AG suppresses COX-2 acting
through the same CB1R-dependent mechanism, and we specu-
lated that CB1R may not be the key molecule responsible for
differential regulation of COX-2 expression upon exposure to
cannabinoids. CB1R is coupled to a PTX-sensitive Gi/o protein,
and activation of CB1R releases Gbg subunits from the GTP-
bound Gai subunit (Howlett, 1998; Pertwee et al., 2010). Earlier
studies show that activation of CB1R is capable of inducing
Gbg-mediated response (Guo and Ikeda, 2004; Wilson et al.,
2001; Yao et al., 2003). We hypothesized that Gbg and Gai
may differentially mediate COX-2 induction or suppression by
exogenousD9-THC or endogenous 2-AG. To test this prediction,
we first overexpressed Gbg subunits by transfection with plas-
mids carrying b1 and g2 subunits in NG108-15 cells, which ex-
press native CB1R (Figures S2A and S2B). Whereas D9-THC still
increased expression of COX-2mRNA in culture transfectedwith
the control vector, it did not increase COX-2 in culture overex-
pressing b1 and g2 subunits (Figure 2A). In subsequent experi-
ments, b1 and g2 subunits were silenced by small hairpin RNA
(shRNA). Knockdown of b1g2 by shRNA suppressing endoge-
nous b1g2 also blocked COX-2 induction by D9-THC in
NG108-15 cells, and the blockade was rescued by concurrently
expressing shRNA-resistant b1g2 (Figures 2A and S2E). This in-
dicates that COX-2 induction by D9-THC is likely mediated
through Gbg. To further confirm that Gbg mediates COX-2 in-
duction by D9-THC, we treated mixed culture of hippocampal
neurons and astroglial cells (5%–10%) with a membrane-
permeable Gbg-binding peptide mSIRK to disrupt the function
of Gbg (Delaney et al., 2007; Goubaeva et al., 2003). As a nega-
tive control, we used a variant mSIRK with a point mutation of
Leu9 to Ala (L9A-mSIRK). As shown in Figure 2B, disruption of
Gbg activity by mSIRK also blocked COX-2 induction by
D9-THC, whereas it failed to block the suppression of COX-2
by 2-AG in response to LPS, a commonly used COX-2 inducer
(Zhang and Chen, 2008). PTX treatment also blocked D9-THC-
induced increase in COX-2. Interestingly, application of 2-AG
failed to suppress D9-THC-induced increase in COX-2 (Figures
2B and S2I). To test the prediction that Gai mediates COX-2 sup-
pressive effect by 2-AG, we silenced Gai using a lentiviral vector
in mixed culture of neurons and astroglial cells (Figure S2C). As
illustrated in Figures 2C and S2D, silencing Gai1, but not Gai2
or Gai3, blocked the suppression of COX-2 by 2-AG in response
to the LPS stimulus, and this blocking effect was rescued by
concurrently expressing shRNA-resistant Gai1 (Figures 2C and
S2E). Knockdown of Gai1, Gai2, or Gai3 did not block COX-2 in-
duction by D9-THC (Figures 2C and S2D). These results indicate
that COX-2 induction by D9-THC is likely mediated via Gbg,1156 Cell 155, 1154–1165, November 21, 2013 ª2013 Elsevier Inc.whereas COX-2 suppression by 2-AG is likely mediated through
Gai1 (Figure S7).
Akt, ERK, p38MAPK, and NF-lB Are Downstream
Signaling of Gbg
To determine downstream signaling pathways of Gbg, we de-
tected phosphorylation of Akt, ERK, and p38MAPK by overex-
pression or knockdown of Gbg in the presence and absence of
D9-THC. As shown in Figures 2D and S2F, D9-THC induced
phosphorylation of these signaling molecules, and the phos-
phorylation was inhibited by knockdown or overexpression of
Gb1g2. Inhibition of phosphorylation of these mediators by
shRNA was rescued by concurrently expressing shRNA-resis-
tant Gb1g2 (Figure 2D). These data indicate that COX-2 induc-
tion by D9-THC is likely through signaling of these downstream
molecules of Gbg. To further characterize this signaling pathway
that regulates COX-2 expression by D9-THC, we targeted
NF-lB, which is a transcription factor regulating expression of
genes, including the COX-2 gene (ptgs2). We observed that
D9-THC induced NF-lB phosphorylation in NG-108-15 cells,
and this phosphorylation was inhibited by overexpression or
knockdown of Gbg and was rescued by concurrently expressing
shRNA-resistant G b1g2 (Figures 2E and S2G). To determine
regulation of COX-2 transcription by NF-lB, we performed a
chromatin immunoprecipitation (ChIP) analysis in mixed culture
of neurons and astroglial cells. As shown in Figure 2E, a binding
activity of NF-lB p65 was detected in the promoter positions
(419 to 428 bp) of ptgs2, and this interaction was enhanced
by D9-THC and inhibited by SC-514, a specific IKKb inhibitor
that inhibits p65-associated transcriptional activation of the
NF-lB pathway. To further confirm the involvement of NF-lB
in D9-THC-induced increase in COX-2, COX-2 expression and
NF-lB phosphorylation by D9-THC were determined in the
absence and presence of SC-514. Inhibition of IKKb blocked
D9-THC-induced COX-2 and NF-lB phosphorylation (Figure 2E).
Phosphorylation of Akt, ERK, p38MAPK, and NF-lB was
confirmed in the hippocampus of animals that received D9-
THC (Figure S2H).
Inhibition of COX-2 Eliminates Impairments in
Hippocampal Long-Term Synaptic Plasticity
If sustained elevation of COX-2 expression and activity following
repeated D9-THC exposure contribute to impairments in long-
term synaptic plasticity and cognitive function, then inhibition
of COX-2 should be able to eliminate or attenuate the impair-
ments. To test this hypothesis, we recorded hippocampal LTP
in mice receiving daily injections of D9-THC (10 mg/kg, the
dosage used by other studies such as Fan et al. [2010], Hoffman
et al. [2007], Puighermanal et al. [2009], and Tonini et al. [2006]),
NS398, D9-THC+NS398, or vehicle for 7 consecutive days. We
found that COX inhibition by NS398 rescued decreased hippo-
campal LTP induced by repeated in vivo exposure to D9-THC
for 7 days both at CA3-CA1 synapses (Figure 3A) and perforant
path synapses in the dentate gyrus (Figure S3A). Similarly,
genetic inhibition of COX-2 also prevented LTP deterioration
induced by D9-THC at both CA3-CA1 synapses (Figure 3B)
and the perforant path (Figure S3B). To verify whether persistent
overexpression of COX-2 impairs LTP, we recorded LTP in
Figure 2. Gbg Subunits Mediate D9-THC-Elevated COX-2 Expression
(A) Overexpression or knockdown of b1 and g2 subunits eliminatesD9-THC-increased COX-2mRNA detected by qPCR in NG108-15 cells. Error bars represent ±
SEM; **p < 0.01 compared with the vehicle control (ANOVA, Fisher’s PLSD, n = 6). NG108-15 cells were transfected with pcDNA3.1 plasmids encoding Gb1 and
Gg2 subunits, the pLL3.7 vector expressing Gb1 and Gg2 shRNA, or the vector expressing shRNA-resistant Gb1g2 in the absence and presence of D
9-THC.
(B) Disruption of Gbg subunits blocks D9-THC-elevated COX-2 but does not prevent suppression of COX-2 by 2-AG in response to LPS stimulus in mixed culture
of hippocampal neurons and astroglial cells (10%). The culture was treated with a membrane-permeable Gbg-binding peptide mSIRK or a single point mutated
(Leu 9 to Ala) Gbg-binding peptide mSIRK (L9A-mSIRK) in the absence and presence of D9-THC, LPS, PTX, 2-AG.
(C) Silencing the Gai1 subunit blocks 2-AG-suppressed COX-2 but does not affect the elevation of COX-2 by D9-THC in mixed culture of neurons and astroglial
cells treated with the lentiviral vector expressing Gai1 shRNA or shRNA-resistant Gai1.
(D) D9-THC induces phosphorylation of Akt, ERK, and p38MAPK. The phosphorylation is inhibited by knockdown of Gbg2, and the inhibition is rescued by
expressing shRNA-resistant Gb1g2.
(E) Left: D9-THC induces phosphorylation of NF-lB, and the effect is blocked by Gb1g2 shRNA in NG108-15 cells. Middle: binding of NF-lB p65 in the promoter
region of the COX-2 gene (ptgs2) by ChIP analysis. Right:D9-THC-induced NF-lBphosphorylation andCOX-2 expression are blocked by IKKb inhibition inmixed
culture of neurons and astroglial cells.
See also Figures S2 and S7.animals repeatedly treated with LPS, which increases COX-2. As
we expected, repeated injection of LPS significantly reduced
LTP, and this decrease was prevented by inhibition of COX-2
(Figure S3C). These data suggest that persistent elevation of
COX-2 in the brain will be detrimental to integrity of synaptic
structure and plasticity. Because a single dose of D9-THC pro-
duced an increase in COX-2 expression, we wondered whether
this increase alters synaptic function. To this end, we recorded
long-term depression (LTD) induced by low-frequency stimula-
tion (LFS) at hippocampal CA3-CA1 synapses and found that
LTD is impaired by a single D9-THC exposure. However, LTD is
normal in COX-2 knockout animals that received a single injec-
tion of D9-THC (Figure S4). This information suggests that a
single D9-THC exposure induces a COX-2-associated impair-
ment in LTD (Mato et al., 2004, 2005).CImpairments in Spatial and Fear Memories by D9-THC
Are Occluded by COX-2 Inhibition
Administration of marijuana or D9-THC impairs learning and
memory. If this impairment is associated with COX-2 induction,
then inhibition of COX-2 would prevent or attenuate the deficits.
To test this prediction, we determined the effect of COX-2 inhibi-
tion on spatial learning and memory using theMorris water maze
test in mice that received repeated D9-THC exposure in wild-
type (WT) and COX-2 KO mice. As shown in Figures 4B and
4C, pharmacological or genetic inhibition of COX-2 prevented
D9-THC-impaired spatial learning and memory. To further
determine the role of COX-2 in D9-THC-impaired memory,
hippocampus-dependent contextual memory was determined
using the fear conditioning protocol (Chen et al., 2006a). As
seen in Figure 4A, repeated D9-THC exposure impaired fearell 155, 1154–1165, November 21, 2013 ª2013 Elsevier Inc. 1157
Figure 3. Inhibition of COX-2 Eliminates
Deficits in LTP by Repeated D9-THC
Exposure
(A) Top: representative field excitatory post-
synaptic potentials (fEPSPs) recorded at hippo-
campal CA3-CA1 synapses from WT animals
repeatedly injected with vehicle, D9-THC (10 mg/
kg), NS398 (10 mg/kg), or D9-THC+NS398 once
daily for 7 consecutive days. LTP was measured
24 hr after cessation of the last injection. Left: time
courses of changes in fEPSP slope under different
treatment. Right: mean values of the potentiation
of fEPSPs averaged from 56 to 60 min following
TBS (n = 6– 8 slices/5–6 animals).
(B) Top: representative fEPSPs recorded from
COX-2 knockout (KO) mice injected with vehicle or
D9-THC (10 mg/kg) once daily for 7 consecutive
days. Left: time courses of changes in fEPSP slope
induced by D9-THC. Right: mean values of the
potentiation of fEPSPs averaged from 56 to 60 min
following TBS (n = 8–12 slices/6–8 animals).
Error bars represent ± SEM; **p < 0.01 compared
with vehicle controls; ##p < 0.01 compared with
D9-THC (ANOVA with Bonferronni post hoc test).
Scale bars in (A1) and (B1), 0.3mV/10 ms. See also
Figures S3 and S4.memory, and this impairment was attenuated by COX-2 inhibi-
tion. These results suggest that COX-2 plays a critical role in
synaptic and cognitive function deterioration consequent to
repeated in vivo D9-THC exposure (Figure S7).
Cataleptic effect and hypomotility are behavioral responses
upon administering D9-THC (Burstein et al., 1989; Long et al.,
2009). We observed that the cataleptic and locomotor depres-
sive effects ofD9-THCwere attenuated or prevented by pharma-
cological or genetic inhibition of COX-2 (Figure S5). This means
that cannabis-elicited catalepsy and locomotor depression are
associated with the COX-2 induction.
Functional Synaptic Integrity in D9-THC-Treated
Animals Is Maintained by COX-2 Inhibition
Impaired long-term synaptic plasticity and memory induced by
D9-THC are largely associated with altered expression and func-
tion of glutamate receptors (Fan et al., 2010; Han et al., 2012).
Recent evidence shows that adolescent chronic treatment with
D9-THC results in reduced density of dendritic spines and
lowered length and number of dendrites in the hippocampus
(Rubino et al., 2009). We used Thy1-GFP-expressing transgenic
mice to detect morphology of dendritic spines (Chen et al.,
2012). As seen in Figure 5A, repeated D9-THC exposure signifi-
cantly reduced density of dendritic spines of CA1 pyramidal neu-
rons, especially mushroom spines in which AMPA and NMDA
receptors are expressed. We found that the reduction in spines
was prevented by pharmacological or genetic inhibition of
COX-2. (We should mention here that the comparatively low1158 Cell 155, 1154–1165, November 21, 2013 ª2013 Elsevier Inc.number of mushroom-type spines in
Figure 5A may be due to the scoring
criteria.) Meanwhile, D9-THC-reduced
expression of PSD-95, an important post-synaptic marker, was rescued by COX-2 inhibition (Figure 5B).
However, D9-THC did not alter expression of synaptophysin
(Syn), a presynaptic marker. This information indicates that
increased COX-2 by repeatedD9-THC exposure decreases den-
dritic spines and postsynaptic density. We show previously that
repeatedD9-THC exposure for 7 days induces CB1R-dependent
decreases in functional and surface expression of AMPA and
NMDA receptor subunits (Fan et al., 2010). We speculated that
reduced expression of glutamate receptor subunits in the hippo-
campus of animals that received repeated in vivo D9-THC
exposure is likely regulated by a homeostatic mechanism. D9-
THC increased synthesis of COX-2 and its reaction product
PGE2, which stimulates glutamate released from presynaptic
nerve terminals and astroglial cells, resulting in an extracellular
accumulation of glutamate (Figure S6A). The increased extracel-
lular glutamate may also result from the reduced uptake of gluta-
mate by glutamate transporters because expression of these
transporters was downregulated by repeated exposure to D9-
THC (Figure S6B). To this end, we used immunostaining to deter-
mine expressions of synaptic and extrasynaptic GluA1, GluN2A,
and GluN2B in the hippocampal CA1 area. As shown in Fig-
ures 5C and 5D, hippocampal expressions of both synaptic
and extrasynaptic GluA1, GluN2A, and GluN2B were signifi-
cantly reduced by repeatedD9-THC exposure, and the reduction
was attenuated or prevented by COX-2 inhibition. This was
consistent with the observations where total and surface
expressions of GluA1, GluN2A, and GluN2B detected by immu-
noblot in WT mice were significantly decreased following
Figure 4. Impaired Spatial and Fear Mem-
ories by Repeated D9-THC Exposure Are
Occluded by COX-2 Inhibition
(A) Impaired fear memory is attenuated by
COX-2 inhibition. 24 hr after a footshock con-
ditioning, animals were administered with D9-
THC (10 mg/kg) or NS398 (10 mg/kg) once
a day for 7 days. Freezing behavior was
recorded 24 hr after the cessation of the last
injections.
(B) COX-2 KO and WT mice received training
in the Morris water maze for 5 days without
any treatments (naive). Starting at day 6,
WT animals received vehicle, D9-THC (10 mg/
kg), NS398 (10 mg/kg), D9-THC+NS398, once
a day for 7 days. COX-2 KO mice received
vehicle or D9-THC (10 mg/kg) for 7 days.
Tests were performed 30 min following the in-
jections.
(C) Probe trial test, which was conducted 24 hr
after the cessation of the last D9-THC injection.
Left: the number of times crossed the target
zone. Middle: the amount of time stayed in the target quadrant. Right: swim speed in different treatments in probe trial tests.
Error bars represent ± SEM; **p < 0.01 compared with the vehicle control; #p < 0.05 and ##p < 0.01 compared with D9-THC (n = 9–12 animals/group, two-way
ANOVA, Bonferronni post hoc test). See also Figures S5 and S7.exposure to D9-THC for 7 days, but the decreases were not seen
in COX-2 knockout mice (Figure 6). These results indicate that
reduced expression of glutamate receptor subunits and density
of dendritic spines are associated with the COX-2 induction ef-
fect of D9-THC (Figure S7).
The Beneficial Effects of Decreasing Ab and
Neurodegeneration by D9-THC Are Preserved in the
Presence of COX-2 Inhibition
A critical issue is whether COX-2 inhibition would eliminate the
beneficial effects of marijuana. To answer this question, we
used 5XFAD APP transgenic mice, an animal model of
Alzheimer’s disease (AD) as described previously (Chen et al.,
2012), to determine whether D9-THC is capable of reducing Ab
and neurodegeneration and whether these effects are retained
when COX-2 is inhibited. As shown Figures 7A and 7B, treatment
of D9-THC once daily for 4 weeks significantly reduced the
numbers of Ab plaques and degenerated neurons in the absence
and presence of Celebrex in AD animals. This information indi-
cates that the beneficial effects of D9-THC are preserved while
COX-2 is inhibited. Meanwhile, we revealed that the reduction
of Ab by D9-THC is not through inhibiting expression of b-site
amyloid precursor protein cleaving enzyme 1 (BACE1), an
enzyme responsible for synthesis of Ab, but is likely through
elevating neprilysin, an important endopeptidase that degrades
Ab (Figure 7C).
DISCUSSION
The results presented here demonstrate that impaired synaptic
and cognitive function induced by repeated D9-THC exposure
is associated with a previously unrevealed CB1R-Gbg-Akt-
ERK/MAPK-NF-lB-COX-2 signaling pathway. It has been long
known that use of marijuana induces neuropsychiatric and
cognitive deficits, which greatly limit medical use of marijuana.CSynaptic and memory impairments are also the consequence
of cannabis abuse. However, the molecular mechanisms under-
lying undesirable effects by cannabis are largely unknown. We
discovered in this study that pharmacological or genetic inhibi-
tion of COX-2 eliminates or attenuates synaptic and memory
impairments elicited by repeated D9-THC exposure, suggesting
that these major adverse effects of cannabis on synaptic and
cognitive function can be eliminated by COX-2 inhibition, which
would broaden the use of medical marijuana.
CB1R is the primary target of cannabinoid exposures causing
synaptic and memory impairments (Lichtman and Martin, 1996;
Hoffman et al., 2007; Puighermanal et al., 2009; Fan et al., 2010;
Han et al., 2012). Previous studies show that the endocannabi-
noid 2-AG suppresses COX-2 via a CB1R-depedent mechanism
in response to proinflammatory and excitotoxic insults (Zhang
and Chen, 2008). Surprisingly, we found in the present study
that the exogenous cannabinoidD9-THC increases COX-2 activ-
ity and expression, which are also mediated via CB1R. We
demonstrate that COX-2 induction by D9-THC is mediated via
Gbg subunits, whereas COX-2 suppression by 2-AG is mediated
via the Gai1 subunit, suggesting that activation of the same
CB1 receptor may induce opposite biological effects. Indeed,
previous studies showed that endogenous cannabinoids and
exogenous D9-THC exhibit different behavioral responses via
CB1R (Long et al., 2009). However, it is still not clear how activa-
tion of CB1R and its coupled Gi/o by the endogenous cannabi-
noid 2-AG results in Gai-mediated suppression of COX-2 in
response to proinflammatory insults but by the exogenous
cannabinoid D9-THC leads to Gbg-mediated induction of
COX-2. Activation of CB1R/Gi/o either by 2-AG or D9-THC
should induce both Gai- and Gbg-mediated effector responses
through different downstream signaling events. For example,
inhibition of N type calcium channel currents by 2-AG appears
to be mediated via Gbg (Guo and Ikeda, 2004), suggesting that
2-AG is also capable of triggering Gbg-mediated responses inell 155, 1154–1165, November 21, 2013 ª2013 Elsevier Inc. 1159
Figure 5. Decreases in Dendritic Spine Den-
sity and Glutamate Receptor Expression
by D9-THC Are Prevented by Inhibition of
COX-2
(A) Two-photon imaging of dendritic spines in CA1
hippocampal pyramidal neurons expressing GFP
of transgenic mice. Top left: representative image
of a CA1 pyramidal neurons. Scale bar, 20 mm. Top
right: representative images of dendritic spine
segments from animals received different treat-
ments. Scale bars, 3 mm. Lower left: spine density
in WT animals, and lower right: in COX-2 knockout
(KO) mice (n = 5 animals/group).
(B) Expression of PSD-95 and synaptophysin (Syn)
in animals treated with D9-THC or NS398 for
7 days (n = 3 animals).
(C) Immunostaining analysis of synaptic and
extrasynaptic glutamate receptor subunits. Left:
schematic of a hippocampal section. The red
dashed-line box marks the sampling field of
immunostaining analysis. Scale bar, 200 mm.
Right: representative GluA1, GluN2A, GluN2B, and
Syn immunoreactivities (scale bar, 5 mm).
(D) Left: enlarged immunosignals of GluA1,
GluN2A, GluN2B, Syn, and their overlay. Scale
bars, 1.5 mm. Right: quantification of synaptic
(colocalized with Syn) and extrasynaptic (no-
colocalized) GluA1, GluN2A, and GluN2B (n = 5
animals/group).
Error bars represent ± SEM; **p < 0.01 compared
with the vehicle control, #p < 0.05, and ##p < 0.01
compared with D9-THC (ANOVA with Fisher’s
PLSD or Bonferronni post hoc tests).addition to Gai-mediated responses. In the case of COX-2
induction, the Gbg-mediated COX-2 induction by D9-THC may
be predominant, which may mask Gai-mediated COX-2 sup-
pression. In addition, our results showing that the beneficial
effects of D9-THC are retained in the presence of COX-2 inhibi-1160 Cell 155, 1154–1165, November 21, 2013 ª2013 Elsevier Inc.tion further suggest that activation of
CB1R by D9-THC may have both Gai-
and Gbg-mediated effector responses. It
is likely that COX-2 induction by D9-THC
may be just one of several Gbg-mediated
effects, and we cannot exclude the possi-
bility that other biological effects are
mediated via Gbg. The divergent roles of
G protein subunits in mediating endoge-
nous and exogenous cannabinoids may
be a consequence the intrinsic mecha-
nisms of CB1R/G protein coupling, such
as the agonist binding sites in the recep-
tor, the efficacy of binding, or different
conformational changes in the receptor/
G protein upon binding with different
agonists.
Synaptic and cognitive impairments
by D9-THC are apparently associated
with alterations in glutamatergic synaptic
transmission and functional expression ofglutamate receptor subunits (Fan et al., 2010; Han et al., 2012;
Monory et al., 2007; Tonini et al., 2006). It has been demon-
strated that cannabinoid exposure leads to downregulation,
internalization, and endocytosis of glutamate receptor subunits
(Fan et al., 2010; Han et al., 2012; Sua´rez et al., 2004). In this
Figure 6. Reduced Expression of Glutamate
Receptor Subunits and Phosphorylation of
CREB by D9-THC Is Rescued by COX-2
Inhibition
(A) Immunoblot analysis of hippocampal expres-
sion of GluR1, NR2A, and NR2B subunits in WT
and COX-2 KO mice treated with vehicle or
D9-THC for 7 days (n = 3).
(B) Surface expression of GluR1, NR2A, and NR2B
in WT and COX-2 KO mice treated with vehicle or
D9-THC for 7 days (n = 4).
(C) Phosphorylation of hippocampal CREB in WT
and KO mice treated with vehicle or D9-THC for
7 days (n = 3).
Error bars represent ± SEM; *p < 0.05 and **p <
0.01 compared with the vehicle control (ANOVA
with Fisher’s PLSD). See also Figures S6 and S7.study, we also demonstrate that density of dendritic spines in
hippocampal neurons is reduced in animals that received D9-
THC for 7 days. The reduced expressions of synaptic and extra-
synaptic of glutamate receptor subunits as well as PSD-95 by
D9-THC are likely associated with elevated extracellular gluta-
mate levels. Indeed, it has been shown that cannabinoids elevate
extracellular glutamate levels, which may result from increased
synaptic and astrocytic release of glutamate or reduced uptake
of glutamate by glutamate transporters (Fan et al., 2010; Ferraro
et al., 2001; Han et al., 2012; Navarrete and Araque, 2008;
Tomasini et al., 2002; Sua´rez et al., 2004; Tonini et al., 2006).
We detected that expression of glutamate transporters is sig-
nificantly decreased in D9-THC exposed animals, and this
decrease is attenuated by COX-2 inhibition (Figure S6). These
previous studies, together with our results, suggest that accu-
mulation of glutamate in the extracellular apartment by repeated
D9-THC exposure contributes to reductions in total and surface
expression of the glutamate receptors and the density of den-
dritic spines.
Earlier studies showed that the levels of the eicosanoid PGE2
in circulation and the brain are elevated in humans and animals
exposed to marijuana or D9-THC, and the elevation could be
antagonized by indomethacin, a nonsteroidal anti-inflammatory
drug (NSAID) (Burstein et al., 1989; Fairbairn and Pickens,
1979, 1980; Perez-Reyes et al., 1991). NSAIDs are nonselective
inhibitors for both COX-1 and COX-2. This suggests that COX-1
and/or COX-2may be involved in marijuana- or D9-THC-inducedCell 155, 1154–1165, Noincrease in PGE2. Although both COX-1
and COX-2 are capable of converting
arachidonic acid (AA) into five primary
prostanoids and prostaglandins (PGD2,
PGE2, PGF2a, PGI2, and TXA2), they
exhibit preferences in synthesizing these
substances. It is evident that PGE2 is
primarily derived from the COX-2 path-
way (Brock et al., 1999; Sang et al.,
2005). Because COX-1 expression is not
affected by D9-THC (Figure S1) and
because COX-2 is expressed both in
constitutive and inducible forms in thebrain, it is likely that COX-2 is responsible for the marijuana- or
D9-THC-induced elevation of PGE2. Our data showing that
D9-THC increases PGE2 in the brain and that this increase is
blocked by COX-2 inhibition support this speculation. Interest-
ingly, D9-THC-induced cataleptic response can be eliminated
by NSAIDs and mimicked by direct administration of PGE2 (Bur-
stein et al., 1989; Fairbairn and Pickens, 1979). We also provide
convincing evidence that pharmacological or genetic inhibition
of COX-2 prevents or attenuates cataleptic and locomotor
depressive responses by D9-THC. Importantly, synaptic and
cognitive deficits following repeated D9-THC exposure are elim-
inated or attenuated by COX-2 inhibition.
The elevated levels of extracellular glutamate byD9-THC result
likely from induction of COX-2, which makes PGE2. It has been
shown that PGE2 stimulates or facilitates both synaptic and
astrocytic release of glutamate (Bezzi et al., 1998; Chen et al.,
2002; Dave et al., 2010; Sang et al., 2005; Sanzgiri et al.,
1999). In fact, COX-2 and PGE2 signaling have been shown to
regulate glutamatergic synaptic transmission and plasticity via
EP2 or EP3 receptors (Akaneya and Tsumoto, 2006; Chen
et al., 2002; Cowley et al., 2008; Sang et al., 2005). It is possible
that D9-THC exposure stimulates COX-2 expression and activity
through CB1R-coupled Gbg subunits and the downstream Akt-
ERK/MAPK-NF-lB signaling pathway, resulting in increase of
COX-2 transcription, expression, and activity, which in turn
enhance the release of PGE2 from neurons and astroglial cells.
Our results show that D9-THC-induced COX-2 expression invember 21, 2013 ª2013 Elsevier Inc. 1161
Figure 7. The Beneficial Effects of Reducing
Ab and Neurodegeneration by D9-THC Are
Preserved in the Presence of COX-2
Inhibition
(A) D9-THC significantly reduces Ab plaques de-
tected using anti-4G8 antibody in 4-month-old
5XFAD APP transgenic (TG) mice in the absence
and presence of COX-2 inhibition. TG mice
received D9-THC (3 mg/kg) or Celebrex (1 mg/kg)
once daily for 4 weeks starting at 3 months of age.
(B) D9-THC significantly reduces degenerated
neurons detected by Fluoro-Jade C (FJC) staining
in 6-month-old TGmice treated with/out Celebrex.
TG mice received D9-THC (3 mg/kg) or Celebrex
(1 mg/kg) once daily for 4 weeks starting at
5 months of age.
(C) D9-THC increases expression of neprilysin
(NEP), but not b-site amyloid precursor protein
cleaving enzyme 1 (BACE1) in TG mice.
Error bars represent ± SEM; **p < 0.01 compared
with the vehicle control (n = 3 to 5 animals/group;
one-way ANOVA, Bonferronni post hoc tests).
Scale bars in (A) and (B), 400 mm.astroglial cells is more pronounced than in neurons. A recent
study also shows that CB1R expressed in astroglial cells is
responsible for LTD and working memory impairment in animals
exposed to cannabinoids (Han et al., 2012). This suggests that
glutamate released from astroglial cells triggered by COX-2-
derived PGE2 and reduced uptake of glutamate by glutamate
transporters in astrocytes resulting from repeated D9-THC expo-
sure may play an important role in extracellular glutamate accu-
mulation. Sustained elevation and accumulation of extracellular
glutamate upon repeated exposure to D9-THC induce downre-
gulation and internalization of glutamate receptor subunits and
reduction in the density of dendritic spines in hippocampal neu-
rons, leading to the deficits in long-term synaptic plasticity and
cognitive function (Figure S7).
It has been well recognized that cannabinoids possess antiox-
idant, anti-inflammatory, and neuroprotective properties (Bahr
et al., 2006; Campbell and Gowran, 2007; Centonze et al.,
2007; Chen et al., 2011; Du et al., 2011; Gowran et al., 2011;
Marchalant et al., 2008; Marsicano et al., 2003; Zhang and
Chen, 2008). Also, cannabis has been used for thousands
of years as medical treatments. However, neuropsychiatric
and cognitive side effects limit medical use of marijuana, espe-
cially for a long-term treatment. The results presented here1162 Cell 155, 1154–1165, November 21, 2013 ª2013 Elsevier Inc.suggest that the unwanted side effects
of cannabis could be eliminated or
reduced—while retaining its beneficial
effects—by administering a COX-2 inhib-
itor or NSAID along with D9-THC for treat-
ments of intractable medical conditions
such as AD. In the present study, we did
observe that brain Ab and neurodegener-
ation in 5XFAD transgenic mice are signif-
icantly reduced by D9-THC, and these
beneficial effects are preserved in the
presence of COX-2 inhibition. We alsodiscovered that D9-THC significantly elevates expression of
neprilysin, an important endopeptidase for Ab degradation.
This suggests that D9-THC is capable of reducing Ab and neuro-
degeneration in an animal model of AD and that the Ab-reducing
effect is likely through elevating expression of neprilysin. This
suggests that D9-THC (brand name: Marinol) may have thera-
peutic potential for prevention and treatment of AD if its undesir-
able side effects (e.g., synaptic and cognitive impairments) can
be eliminated by COX-2 inhibition. In particular, there are no
effective medications currently available for preventing and
treating AD or halting disease progression. Our results also sug-
gest that selective COX-2 inhibitors or NSAIDs may be useful for
treating the neuropsychological and cognitive side effects of
cannabis abuse.
EXPERIMENTAL PROCEDURES
Animals
C57BL/6, CB1 knockout, Thy1-EGFP transgenic, COX-2 knockout, and
5XFAD APP transgenic mice were used in the present study.
Cell Culture
Relative pure hippocampal neurons (astroglial cells < 2%), mixed neurons
and astroglial cells (astroglial cells 10%), astroglial cell-enriched (astroglial
cells > 95%), and NG108-15 cell cultures were made as described previously
(Sang et al., 2005; Zhang and Chen, 2008).
Electrophysiological Recordings
Hippocampal LTP both at CA3-CA1 and perforant path synapses were re-
corded in acutely hippocampal slices and induced by a q-burst stimulation
(TBS) as described previously (Hoffman et al., 2007).
Immunoblots
Western blot assay was conducted using specific antibodies (Table S1) to
determine expressions of COX-2, glutamate receptor subunits, PSD-95, G
protein subunits, phosphoproteins, BACE1, and neprilysin in hippocampal tis-
sue and/or in cultured cells as described previously (Chen et al., 2012). Surface
biotinylation assays were performed to determine surface expression of gluta-
mate receptor subunits in hippocampal slices as described previously (Fan
et al., 2010).
Transfection of Plasmid and Lentiviral Vectors
NG108-15 cells were used for transfection of the pcDNA3.1 plasmid encoding
Gb1 and Gg2 subunits or the pLL3.7 vector expressing scramble, Gb1 and
Gg2 shRNA, and shRNA-resistant Gb1g2. Mixed culture of neurons and astro-
glial cells was used for transfection of the pLL3.7 lentiviral vector expressing
scramble, Gai1 shRNA, and shRNA-resistant Gai1.
qRT-PCR
The iScript complementary (cDNA) synthesis kit (BioRad) was used for
the reverse transcription reaction. Real-time RT-PCR specific primers for
COX-2, b1, g2, and GAPDH were synthesized by IDT. Samples were
compared using the relative CT method as described previously (Zhang and
Chen, 2008).
ChIP Analysis
ChIP analysis was performed to determine the binding activity of NF-lB in the
promoter of the COX-2 gene.
PGE2 Assay
PGE2 in hippocampal tissue was detected using PGE2 enzyme immunoassay
kit (Cayman Chemical) according to the procedure described by the manufac-
turer (Zhang and Chen, 2008).
Immunostaining and Histochemistry
Ab plaques, degenerated neurons, and glutamate receptor subunits in cryo-
stat sectioning brain slices were performed as described previously (Chen
et al., 2012; Li et al., 2011).
Two-Photon Imaging
Morphology of dendritic spines in hippocampal CA1 pyramidal neurons was
determined in GFP-expressing transgenic mice using a two-photon laser
scanning microscope as described previously (Chen et al., 2012). Shape,
size, and density of spines were measured from the three-dimensional recon-
structions using NeuronStudio version 0.9.92.
Behavioral Tests
The classic Morris water maze and fear conditioning tests were performed
to determine spatial and fear memory as described previously (Chen
et al., 2006a, 2012). The ‘‘open field’’ test was conducted to detect the loco-
motor activity, and the bar test was used to detect catalepsy (Egashira et al.,
2007).
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